Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC

15. september 2026 opdateret af: Pharmicell Co., Ltd.

Et åbent, enkeltcenter, fase 1-studie til evaluering af sikkerheden ved kræftimmunterapi med autologe dendritiske celler hos patienter med metastatisk kastrationsresistent prostatacancer (mCRPC)

The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

Cellgram-DC-PC is an autologous dendritic cell-based cancer immunotherapy developed for patients with metastatic castration-resistant prostate cancer (mCRPC). This was a Phase 1, single-center, open-label clinical trial designed to characterize the safety profile of Cellgram-DC-PC following administration in patients with mCRPC.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

3

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Seoul, Sydkorea
        • Asan medical center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

19 år til 79 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  1. 19 and under 80 years

  2. Histologically confirmed prostate adenocarcinoma

  3. Patients with stage M1a or M1b with extrapelvic lymph nodes and bone metastases

  4. Patients diagnosed with castration-resistant prostate cancer after failure of male hormone deprivation therapy (Castrate levels of testosterone <50 ng/dL) and If either a or b is satisfied:

    1. Biochemical progression: Prostate Specific Antigen (PSA) increases three times in a row at 1 week intervals, two 50% increases compared to the lowest point, PSA> 2ng/mL, or
    2. Radiological progression: appearance of new lesions; 2 or more new lesions on the bone scan
  5. Asymptomatic or mild patients after previous treatment

    1. Patients who have not used narcotic analgesics within 21 days prior to enrollment
    2. Patients with an average weekly pain of less than 4 on the Visual Analogue Scale(VAS) (out of 10)
  6. Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of gonadotropin is allowed

  7. Whole body performance status: European Cooperative Oncology Group(ECOG) 0~1

  8. Patients whose life expectancy is at least 6 months or longer

  9. Hb ≥ 8.0g/dL, Absolute Neutrophil Count(ANC) ≥ 1,500/mm3, Platelets ≥ 100,000/mm3

  10. Serum Creatinine ≤ 2.0 x Upper Limit of Normal(ULN) or Calculated Creatinine Clearance > 30mL/min

  11. Total Bilirubin ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase (AST)/Alanine aminotransferase(ALT) <2.5 x ULN

  12. Patients who did not receive surgery, radiation therapy, or immunotherapy within the last 6 weeks and recovered from side effects

  13. Patients who agreed to use medically recognized contraceptive methods during the clinical trial participation period

  14. Patients who voluntarily participated in clinical trials and signed the Informed Contents Form (ICF)

Exclusion Criteria:

  1. Patients who have a local recurrence and are scheduled for local treatment.
  2. Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
  3. Patients with visceral metastases (metastases to the lungs, liver, adrenal glands, peritoneum, brain, etc.)
  4. Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or anti-PDL2, etc.) or participated in immunotherapy-related clinical trials
  5. Patients with active autoimmune diseases requiring systemic immunosuppression treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or steroids for disease control)
  6. Patients with medical conditions requiring continuous or intermittent administration of systemic steroids or immunosuppressants
  7. Patients who received blood products (limited to whole blood products) within 4 weeks of screening criteria, or patients who received colony stimulating factors (Colony Stimulating Factor or recombinant Erythropoietin)
  8. Patients with a history of organ or hematopoietic stem cell transplantation
  9. Patients with acute or chronic infections requiring systemic treatment
  10. Patients known to be infected with human immunodeficiency virus (HIV)/serum positive
  11. Patients with active hepatitis A, B or C
  12. Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) Immunoglobulin M positive patients)
  13. Patients expected to require therapeutic biotherapy or immunotherapy
  14. Patients who received live virus vaccines (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist, etc.) within 30 days
  15. Patients with a history of anaphylaxis to gentamicin
  16. Others, if the person in charge of the study determines that it is not suitable for the clinical trial

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Cellgram-DC-PC

Participants received Cellgram-DC-PC by subcutaneous injection near the inguinal lymph nodes.

Patients received three subcutaneous injections of Cellgram-DC-PC (autologous dendritic cells) near the inguinal lymph nodes at Weeks 0, 2, and 4.

Andre navne:
  • Autolog dendritiske celle anti-cancer immuncelleterapi til behandling af prostatacancer

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Adverse Event
Tidsramme: From informed consent to the end of treatment at Week 28.

Adverse events (AEs) were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

From informed consent to the end of treatment at Week 28.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Immune Response
Tidsramme: At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.

Tumor antigen-specific immune responses were evaluated by measuring changes in serum IFN-γ and IL-12 levels and antigen-specific T-cell responses following administration of the investigational product.

At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
Change in Prostate-Specific Antigen (PSA)
Tidsramme: At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.

Exploratory efficacy was evaluated by measuring changes in prostate-specific antigen (PSA) levels from pre-treatment (Week 0) to post-treatment assessment.

At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: BUMJIN LIM, Ph.D, Asan Medical Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. juli 2021

Primær færdiggørelse (Faktiske)

15. februar 2022

Studieafslutning (Faktiske)

30. juni 2022

Datoer for studieregistrering

Først indsendt

22. oktober 2020

Først indsendt, der opfyldte QC-kriterier

2. november 2020

Først opslået (Faktiske)

4. november 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data will not be made available to other researchers.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner